The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
DLBS1033 is bioactive protein fraction which extracted from Lumbricus rubellus earthworm.
This earthworm comes from Pengalengan, West Java, Indonesia. DLBS1033 possesses 8 major
proteins with molecular weight below 100 kDa, so its named as Lumbricus Low Molecular weight
Proteins (LLP). This enzym can be transported to the bloodstream via intestinal epitel.
Structure of DLBS1033 looks like lumbrokinase. Lumbrokinase is enzym that consist of 6
isoenzyme serine protease. As a drug that consists of serin protease enzym, suspected that
the mechanism of action of DLBS1033 similar with lumbrokinase, especially as plasminogen
activator in fibrinolytic system. In vitro study by Trisina et al showed that DLBS1033 has
fibrinogenolytic activities on fibrinogen α, beta, and gamma chain, decreasing platelet
aggregation and clotting time was prolonged. Until now, the mechanism of action and effects
of DLBS1033 on human fibrinolytic and coagulation system still unknown. Therefore, the aim of
this clinical trial is to evaluate the effects of DLBS1033 on human fibrinolytic and
coagulation system on healthy subjects.